Page last updated: 2024-08-21

isoxazoles and tivozanib

isoxazoles has been researched along with tivozanib in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bichat, F; Fujiwara, Y; Guilbaud, N; Hasegawa, K; Isae, T; Kubo, K; Miura, T; Nakamura, K; Shibuya, M; Suzuki, R; Taguchi, E; Takahashi, K; Yamamoto, A1
Isoe, T; Miura, T; Nakamura, K; Shibuya, M; Taguchi, E1

Other Studies

2 other study(ies) available for isoxazoles and tivozanib

ArticleYear
KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties.
    Cancer research, 2006, Sep-15, Volume: 66, Issue:18

    Topics: Animals; Antineoplastic Agents; Capillary Permeability; Cell Line, Tumor; Endothelial Cells; Humans; Isoxazoles; Magnetic Resonance Imaging; Mice; Neoplasms; Neovascularization, Pathologic; NIH 3T3 Cells; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Random Allocation; Rats; Rats, Nude; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays

2006
Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model.
    Cancer science, 2008, Volume: 99, Issue:3

    Topics: Animals; Antineoplastic Agents; Ascites; Cell Line, Tumor; Colonic Neoplasms; Disease Models, Animal; Humans; Isoxazoles; Neovascularization, Pathologic; Peritoneal Neoplasms; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Rats; Rats, Inbred F344; Receptors, Vascular Endothelial Growth Factor

2008